Biased Ligands. Better Drugs.

Investor Inquiries:Erin Clark
Snr Director Corporate Strategy & IR
610-354-8840 x355
ir@trevena.com

PR/Media Inquiries:pr@trevena.com

Trevena to Present at the Oppenheimer & Company 28th Annual Healthcare Conference
3/14/18

Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at the Oppenheimer & Company 28th Annual Healthcare Conference on Wednesday, March 21, 2018, at 2:45 p.m. EDT in New York, NY.

To join a live audio webcast of the presentation, please visit the Investor section of the Company’s website. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.

About Trevena

Trevena, Inc. is a biopharmaceutical company focused on providing better, safer therapies to patients in pain.  The Company has leveraged breakthrough science to discover and develop its investigational product OLINVO™ (oliceridine) Injection for the management of moderate-to-severe acute pain.  OLINVO has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration, and is intended to provide healthcare providers an innovative new option for patients who require an intravenous opioid. The Company also has an early stage pipeline of new chemical entities targeting novel mechanisms of action, including TRV250 for acute migraine, neuropathic pain, and other indications.  

Contacts

Trevena, Inc.

Investors:

Jonathan Violin, Ph.D.
Senior Vice President, Scientific Affairs & Investor Relations Officer
610-354-8840 x231
jviolin@trevena.com

or

Media:

Public Relations
PR@trevena.com

Copyright © Trevena, Inc.